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Abstract
The efficacy of emodepside plus toltrazuril oral sus-
pension for dogs (Procox®, Bayer) against Trichuris 
vulpis was evaluated in a controlled, blinded and 
randomised laboratory study. Twenty naturally 
infected dogs were included. Dogs in the treatment 
group received the minimum therapeutic dose of 
0.45 mg emodepside and 9 mg toltrazuril per kg 
body weight, while dogs in the control group were 
left untreated. Efficacy was calculated based on 
worm counts after necropsy on Day 7 post treat-
ment. Additionally, all faeces were collected and 
examined for expelled worms. The treatment was 
100 % effective. A total of 233 adult worms (geo-
metric mean 17.0) and 3 immature adult worms 
were found in the control group at necropsy. Ade-
quacy of infection was demonstrated. The treated 
group excreted a total of 186 adult worms within 
2 days after treatment. Additionally, all dogs were 
co-infected with Uncinaria stenocephala. Efficacy 
against this parasite was 99.8 %. No side effects 
of the treatment were observed. This study dem-
onstrates that in addition to the formerly proven 
efficacy against Toxocara canis, Ancylostoma cani-
num and Uncinaria stenocephala, emodepside 
plus toltrazuril suspension is also effective against 
T. vulpis and thus represents a convenient treat-





Trichuris vulpis is a blood-feeding intestinal nem-
atode of wild and domestic canids worldwide. Its 
common name “whipworm” is derived from the 
adult worm’s body shape with a thick, whip han-
dle-like posterior part, pointing into the intestinal 
lumen, and a long and slender anterior part which 
is embedded in the mucosa, mainly of the caecum. 
Continual movement of the head leads to tissue 
damage and may result in haemorrhagic colitis 
(Kirkova and Dinev 2005) and severe electrolyte 
imbalances, in some cases mimicking symptoms 
of Addison’s disease (Ruckstuhl et al. 2002; Venco 
et al. 2011). The life cycle is direct, and after a pre-
patent period of 9–10 weeks typical lemon-shaped, 
highly resistant eggs are released into the environ-
ment that may remain infective for several years. 
After ingestion, the larvae hatch in the small intes-
tine and penetrate the mucosa, provoking desqua-
mation of the epithelium, hyperaemia and mucoid 
dystrophy. The histotropic phase in the small 
intestine takes about two weeks before the large 
intestine is colonised (Kirkova and Dinev 2005). 
Due to the long prepatent period and egg inges-
tion being the only source of infection, T. vulpis is 
rarely found in dogs less than three months of age 
(Barutzki and Schaper 2011). While prevalence can 
vary regionally and in private dogs mostly does not 
exceed 5 % (Epe et al. 2004; Barutzki and Schaper 
2003; Riggio et al. 2013; Sager et al. 2006), values 
of up to 59.4 % can be found in stray dogs and ken-
nel dogs (Capelli et al. 2006). 
Emodepside plus toltrazuril suspension (Procox®, 
Bayer) is a combined nematodicide and coccidiocide 
for the treatment of dogs, including puppies from 
two weeks of age, with suspected or demonstrated 
mixed infections of nematodes (Toxocara canis, 
Ancylostoma caninum, Uncinaria stenocephala) 
and coccidia (Isospora ohioensis-complex, Isospora 
canis [EMA 2011; Altreuther et al. 2011a, 2011b; 
Schimmel et al. 2011]). Recently, efficacy and safe-
ty of the formulation was also demonstrated in cats 
(Petry et al. 2011a, 2011b). Especially in breeding 
facilities, co-infection with nematodes and coccidia 
is a common finding (Seeliger 1999; Bode 1999) 
and the impact on growth and development may 
be significant (Daugschies et al. 2000; Junker and 
Houwers 2000).
The present study was designed to evaluate the 
efficacy of the emodepside plus toltrazuril suspen-
sion against T. vulpis. 
Materials and methods
This dose confirmation study was conducted as 
a negative controlled, randomised and blinded 
laboratory study in accordance with VICH guide-
line 9 “Good Clinical Practice” (July 2000) and 
the anthelmintic guidelines VICH GL7 “Efficacy 
requirements for anthelmintics: general require-
ments” (December 2000) and VICH GL 19 “Effi-
cacy of anthelmintics: specific recommendations for 
canines” (July 2001).
Study animals
The study population consisted of 20 natural-
ly infected cross-breed dogs (16 female/4 male, 
mainly < 12 months old) that were owned by Clin-
Vet International (Pty) Ltd and weighed between 
4.8 and 12.8 kg. After an acclimatisation period 
of seven days, the dogs were randomised to two 
study groups based on body weight and gender. 
Each study group contained ten dogs, and uniquely 
numbered collar tags were used to identify the ani-
mals. Fitness for inclusion was demonstrated by at 
least two faecal egg counts (FEC) of ≥ 60 T. vulpis 
eggs per gram faeces, good health as determined at 
two clinical examinations performed on Day –7 and 
–1 and absence of recent treatments with drugs 
that could influence the study results, especially 
macrocyclic lactones. As the dogs were naturally 
infected, co-infections with other parasites were 
expected. The dogs were individually housed in 
pens throughout the study. Commercial dog food 
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(Eukanuba Puppy and Junior – Medium) was fed 
once per day at the recommended rates and tap 
water was provided ad libitum. 
Treatment and health observations
On Day 0, dogs assigned to group 2 were treated 
with the minimum therapeutic dose of 0.45 mg 
emodepside and 9 mg toltrazuril per kilogram 
body weight (b.w.), corresponding to 0.5 ml oral 
suspension per kg b.w. The appropriate volume 
was applied using syringes with a 0.1 ml scale 
and care was taken to ensure that the full dose 
was swallowed and no substance was lost. Dogs in 
group 1 served as negative control and were left 
untreated. Clinical assessments including behav-
iour, respiration, salivation/vomiting, eyes, loco-
motion/musculature, feed consumption and faeces 
were conducted pre treatment, 1, 2 and 4 hours 
after treatment and once daily on Day 1 and 2. Spe-
cial attention was paid to vomitus or regurgitation 
at dosing and additionally 30 minutes after dos-
ing. Observations on the general health of the dogs 
were performed on all other study days. 
Faecal examinations
FEC’s for study inclusions were performed using 
McMaster method. All dogs were carefully moni-
tored for spontaneously excreted worms and worms 
expelled after treatment. For this purpose, total 
faeces were collected individually from each dog 
on a daily basis between Day –3 and Day 7. Using 
sieving and microscopic evaluation, all worms 
expelled in the faeces were recovered and pre-
served. Whenever nematodes other than T. vulpis 
were detected, these were counted and processed in 
the same manner as the target parasite. Cestodes 
were only recorded as present or absent, without 
any quantification.
Necropsy
Euthanasia and necropsy were performed on Day 
7. The digestive tract from the beginning of the 
stomach to the rectum was removed and the small 
and large intestines were processed separately. 
The intestinal contents and the results of several 
mucosal strippings were washed over sieves with 
apertures of 150 µm and examined under a stereo-
microscope. All nematode parasites collected at 
necropsy were counted and identified to genus, 
species and developmental stage.
Efficacy determination and statistical analysis
To assess the adequacy of infection in the control 
group, recommendations in VICH guidelines 7 and 
19 were followed. These require a minimum of 
6 control animals with at least 5 worms each. Addi-
tionally, the lower 95 % confidence limit should be 
greater than 10 % of the central tendency. The geo-
metric mean was used for this calculation as all 
worm counts in the control group were > 0. 
Percentage efficacy was calculated according to the 
following formula, recommended by VICH guide-
line 7 and the WAAVP guideline for evaluating the 
efficacy of anthelmintics for dogs and cats (Jacobs 
et al. 1994):




N1:  geometric mean of worm count for the  
control group
N2:  geometric mean of worm count for the  
treatment group
Due to the presence of zero-values, all counts were 
modified by adding 1 prior to log transformation 
and subtracting 1 from the antilog value. To test 
for treatment group effects, the data were analysed 
using the non-parametric Wilcoxon rank sum test 
(two-tailed, α = 0.05).
Results
Mild changes in faecal consistency were occasion-
ally observed in both study groups pre and post 
treatment and were not considered to be treat-
ment-related. Results of the parasitological evalu-
ations for T. vulpis are summarised in Table 1. 
Requirements for the adequacy of infection in the 
control group were fulfilled for adult worms. A total 
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of 233 adult (range 6 to 71) and 3 immature adult 
T. vulpis were recovered from the control group at 
necropsy. No worms were recovered in the trea ted 
group, thus the efficacy was 100 % (p < 0.0001) 
based on adult and as well as on total worm bur-
dens. From the faeces collected after Day 0, a total 
of 186 worms were recovered from the treated 
group and all but one dog excreted five or more 
worms after treatment (range 1 to 56). Except for 
10 worms that were found on Day 2, all worms were 
recovered on Day 1. No worms were found later 
than Day 2. In the control group, one spontane-
ously expelled worm was found on Day 4. During 
pre treatment faecal examinations, one spontane-
ously expelled worm was found in the control group 
and a total of four worms were recovered from three 
dogs in the treated group.
Besides the target parasite T. vulpis, the follow-
ing helminth species were detected during faecal 
examinations and at necropsy: Uncinaria steno-
cephala, Ancylostoma caninum, Toxocara canis, 
Dipylidum caninum and Taenia sp. Only U. steno-
cephala was found in meaningful numbers that 
fulfilled the requirements for the adequacy of 
infection and allowed for efficacy calculations. A 
total of 1,993 adult worms (range 80–429) and two 
Table 1 Efficacy of emodepside plus toltrazuril suspension against T. vulpis in naturally infected dogs
Group Dog no. FEC pre treat-
ment (eggs  
per gram 
faeces)*
No. of worms 
expelled post 
treatment
Worms recovered at necropsy Efficacy
No. of adult / immature 
adult worms




1 86.7 0 23/0
17.0 / 17.6 –
2 93.3 0 13/0
3 60.0 0 6/0
4 773.3 1 71/0
5 340.0 0 30/0
6 46.7 0 8/0
7 233.3 0 8/0
8 166.7 0 40/0
9 273.3 0 28/0
10 73.3 0 6/3
Group 2
treatment
11 146.7 15 0/0
0 / 0 100 %
12 133.3 56 0/0
13 113.3 1 0/0
14 126.7 10 0/0
15 66.7 5 0/0
16 86.7 26 0/0
17 93.3 17 0/0
18 186.7 10 0/0
19 46.7 11 0/0
20 260.0 35 0/0
* Arithmetic mean of three evaluation dates
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immature adult worms were found in the control 
group at necropsy (geometric mean = 166.3). Nine 
of ten treated dogs were negative for U. steno-
cephala at necropsy (geometric mean = 0.3). The 
calculated efficacy was 99.8 % (p < 0.0001). All but 
one dog expelled 5 or more worms in the faeces 
after treatment in group 2 resulting in a total of 
1,484 U. stenocephala (range 1–870).
Discussion
The study presented here demonstrated 100 % 
efficacy of emodepside plus toltrazuril suspension 
against adult T. vulpis in naturally infected dogs. 
The oral suspension is the third introduction of 
emodepside as a novel nematodicide in veterinary 
medicine. Efficacy of emodepside against T. vulpis 
has already been demonstrated for the tablet for-
mulation “Profender® tablets for dogs” (Bayer) 
which is a combination product of emodepside and 
praziquantel. The tablet formulation was 100 % 
effective against adult T. vulpis and 99.9 %/100 % 
effective against immature adult T. vulpis in exper-
imentally and naturally infected dogs (Schimmel 
et al. 2009). 
Emodepside plus toltrazuril suspension is indi-
cated for the treatment of dogs infected with or at 
risk of mixed infections of nematodes and coccidia. 
Especially in young puppies, coccidiosis can be 
fatal, thus this age group is the main target for a 
combined treatment. Although T. vulpis is mainly 
found in dogs older than three months of age, the 
demonstrated efficacy of the suspension against 
this parasite is beneficial. The high reproductive 
rate of T. vulpis together with an extreme resist-
ance of the eggs can result in a heavily contami-
nated environment, particularly in facilities where 
dogs have limited roaming space, as sometimes 
seen in kennels and breeding facilities. Similar epi-
demiological aspects apply for intestinal coccidia-
like Isospora sp. Although hygiene measures play 
an important role, it is unlikely that this parasite 
can be eliminated from a facility by decontami-
nation. Thus, treatment of carrier animals, rep-
resented by older dogs shedding oocytes without 
displaying clinical symptoms, may additionally be 
indicated to reduce the infection pressure. 
The demonstrated efficacy against T. vulpis com-
pletes the range of intestinal nematodes affected 
by emodepside plus toltrazuril suspension. It can 
be concluded that Procox® oral suspension for 
dogs provides a unique treatment option against 
the most common intestinal nematodes when-
ever a simultaneous treatment against coccidia is 
indicated.
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